Biopharmaceutical
Pharmaceutical
Health

AbbVie

$80.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.39 (-0.48%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AbbVie and other stocks, options, ETFs, and crypto commission-free!

About

ABBVIE INC., also called AbbVie, is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. Read More The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.

Employees
30,000
Headquarters
North Chicago, Illinois
Founded
2013
Market Cap
119.52B
Price-Earnings Ratio
22.46
Dividend Yield
4.28
Average Volume
7.18M
High Today
$80.91
Low Today
$80.06
Open Price
$80.78
Volume
1.43M
52 Week High
$113.79
52 Week Low
$75.77

Collections

Biopharmaceutical
Pharmaceutical
Health
Manufacturing
Cancer Prevention
Technology
2013 IPO
US

News

Seeking Alpha8h

Biotech Analysis Central Pharma News: AbbVie's Trouble, Merck KGaA's Bad Streak, Puma's Positive Data

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.

152
Yahoo Finance11h

AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

AbbVie, Inc. ABBV announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug, Venclexta (venetoclax) for the treatment of multiple myeloma. The decision was taken after, in the ongoing phase III BELLINI study, a higher proportion of deaths were observed in the Venclexta arm compared to the control arm of the study. Following the observation, it has been instructed that until the data is further analyzed, no new patients should be enrolled in any studies of Venclex...

56
Seeking Alpha13h

What Investors Are Missing About AbbVie

It looks as if AbbVie's (NYSE:ABBV) glorious days are over. The stock is down almost 30% from its 52-week high and down more than a third from its all-time high set in January 2018. It is substantially underperforming the S&P 500 this year with a performance of -12% compared to the S&P's 13% total return gain. Source: Seeking Alpha - Momentum statistics Are the glory days really over? What has changed since January 2018 that could warrant such a big decline in the stock price? Is the market overreacting o...

162

Earnings

$1.38
$1.63
$1.89
$2.14
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 26, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.